Patel Virendra K, Acharya Leelavathi D, Rajakannan Thiyagu, Surulivelrajan Mallayasamy, Guddattu Vasudeva, Padmakumar Ramachandran
Post Graduate Student, Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India.
Australas Med J. 2011;4(1):9-14. doi: 10.4066/AMJ.2011.450. Epub 2011 Jan 31.
The potential drug-drug interaction (pDDI) increases as the number of concomitant medications increases. Patients with cardiovascular disorders are at higher risk for drug- drug interactions because of the types and number of drugs they receive. While drug interactions are reported to be common, there is no published report of the prevalence of such interactions among Indian cardiac patients. The aim of the present study was to identify the pattern of pDDI and document any observed interaction. It was also planned to evaluate the demography of patients and correlate it with the drug-drug interactions.
A prospective observational study from Oct 2007 to Apr 2008 was carried out in 'cardiology department' of a hospital in South India. Those patients who were taking at least two drugs and had a hospital stay of at least 48 hours were included in the study. The medications of the patients were analyzed for possible interactions. Factors associated with pDDI were studied. The actual interactions that were observed during the hospital stay in the study subjects were documented.
A total of 812 patients were included in the study. 388 pDDIs were identified among 249 patients. The incidence of pDDI was 30.67%. The most common potential interactions were between aspirin & heparin (29.38%), and clopidogrel & heparin (7.21%). Drug classes most commonly involved were antiplatelets, anticoagulants and diuretics. Majority of interactions were of moderate severity, delayed onset, and pharmacodynamic in nature. Total 68 actual interactions were observed in the observed cases.
The present study identified pDDIs and also documented interactions in cardiovascular patients. Factors which had correlation with adverse drug interactions were identified. This study highlights the need for screening prescriptions of cardiovascular patients for pDDIs and proactive monitoring of patients who have identified risk factors; this helps in detection and prevention of possible adverse drug interactions.
随着联用药物数量的增加,潜在药物相互作用(pDDI)也会增加。心血管疾病患者由于所服用药物的种类和数量,发生药物相互作用的风险更高。虽然据报道药物相互作用很常见,但尚无关于印度心脏病患者中此类相互作用发生率的公开报告。本研究的目的是确定pDDI的模式并记录任何观察到的相互作用。还计划评估患者的人口统计学特征并将其与药物相互作用相关联。
2007年10月至2008年4月在印度南部一家医院的“心脏病科”进行了一项前瞻性观察研究。纳入那些服用至少两种药物且住院至少48小时的患者。分析患者的药物以查找可能的相互作用。研究与pDDI相关的因素。记录研究对象住院期间观察到的实际相互作用。
共有812名患者纳入研究。在249名患者中识别出388种pDDI。pDDI的发生率为30.67%。最常见的潜在相互作用是阿司匹林与肝素之间(29.38%)以及氯吡格雷与肝素之间(7.21%)。最常涉及的药物类别是抗血小板药、抗凝药和利尿剂。大多数相互作用为中度严重程度、延迟发作且为药效学性质。在观察病例中总共观察到68次实际相互作用。
本研究识别出了心血管患者中的pDDI并记录了相互作用。确定了与不良药物相互作用相关的因素。本研究强调需要对心血管患者的处方进行pDDI筛查,并对已识别出风险因素的患者进行主动监测;这有助于检测和预防可能的不良药物相互作用。